COTAM – September 5, 2026 (Saturday)

Block 5

Metastatic NSCLC with Driver Mutation

Moderator: Dr. Kamilla Fernanda (AM) | Discussant: Dr. Aline Hada

8:00 AM – 8:20 AM
Metastatic HER2-Positive Disease: Where Are We Today?
Dr. William Fuzita (AM)

8:20 AM – 8:40 AM
EGFR-Mutated Metastatic NSCLC – Monotherapy or Intensified Treatment: What Is the Best Path Forward?
Dr. Filipe Luís Vasconcelos Visani (BA)

8:40 AM – 9:00 AM
ALK-Mutated Metastatic NSCLC – The Battle Between Generations and the Challenges of Sequencing
Dr. Ana Carolina Machado da Silva (AM)

9:00 AM – 9:20 AM
Is There a Role for ADCs After First-Line Progression in EGFR-Mutated NSCLC?
Dr. Aline Hada (AM)

9:20 AM – 9:40 AM
J&J Symposium
EGFR-Mutated NSCLC: Unmet Needs Remain
Dr. Flávio Augusto Ferreira da Silva (SP)

9:40 AM – 10:00 AM
Discussion Panel
All Speakers

Block 6

Metastatic NSCLC Without Driver Mutation

Moderator: Dr. Kamilla Fernanda (AM) | Discussant: Dr. Adelaide Portela

10:30 AM – 10:50 AM
Pre-Analytical Care of Tissue Samples
Dr. Jonathan dos Santos – AstraZeneca

10:50 AM – 11:10 AM
Challenges in Choosing First-Line Treatment for Metastatic NSCLC Without Driver Mutations
Dr. Poliana Signorini (AM)

11:10 AM – 11:30 AM
Advanced Disease After First-Line Progression – Are We in the Era of ADCs?
Dr. Gabriel Kamei (AM)

11:30 AM – 11:50 AM
Management of Endocrinopathies Secondary to New Classes of Cancer Treatment (Immunotherapies, ADCs, Targeted Therapies)
Dr. Hércules Marques (AM)

11:50 AM – 12:10 PM
Discussion Panel
All Speakers

2:00 PM – 2:20 PM
Case 01 – Early/Resectable Disease
Dr. Marcos André (AM)

2:20 PM – 2:40 PM
Case 02 – Locally Advanced/Unresectable Disease
Dr. Alfredo Reich (AM)

3:00 PM – 3:20 PM
Case 03 – Advanced Disease Without Driver Mutation
Dr. Aline Hada (AM)

3:20 PM – 3:40 PM
Case 04 – Advanced Disease with Driver Mutation
Dr. Emmanuelly Duarte (AM)

3:40 PM – 4:00 PM
Discussion Panel
All Speakers